JP2013501058A5 - - Google Patents

Download PDF

Info

Publication number
JP2013501058A5
JP2013501058A5 JP2012523701A JP2012523701A JP2013501058A5 JP 2013501058 A5 JP2013501058 A5 JP 2013501058A5 JP 2012523701 A JP2012523701 A JP 2012523701A JP 2012523701 A JP2012523701 A JP 2012523701A JP 2013501058 A5 JP2013501058 A5 JP 2013501058A5
Authority
JP
Japan
Prior art keywords
formulation
antibody
dma
dmso
preparation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012523701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501058A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/044258 external-priority patent/WO2011017330A1/en
Publication of JP2013501058A publication Critical patent/JP2013501058A/ja
Publication of JP2013501058A5 publication Critical patent/JP2013501058A5/ja
Pending legal-status Critical Current

Links

JP2012523701A 2009-08-04 2010-08-03 低減された粘性を有する濃縮ポリペプチド製剤 Pending JP2013501058A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23114009P 2009-08-04 2009-08-04
US61/231,140 2009-08-04
PCT/US2010/044258 WO2011017330A1 (en) 2009-08-04 2010-08-03 Concentrated polypeptide formulations with reduced viscosity

Publications (2)

Publication Number Publication Date
JP2013501058A JP2013501058A (ja) 2013-01-10
JP2013501058A5 true JP2013501058A5 (https=) 2013-09-12

Family

ID=43544629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012523701A Pending JP2013501058A (ja) 2009-08-04 2010-08-03 低減された粘性を有する濃縮ポリペプチド製剤

Country Status (15)

Country Link
US (1) US20130236448A1 (https=)
EP (1) EP2461677A4 (https=)
JP (1) JP2013501058A (https=)
KR (1) KR20120047995A (https=)
CN (1) CN102573459A (https=)
AU (1) AU2010279569A1 (https=)
BR (1) BR112012002596A2 (https=)
CA (1) CA2769221A1 (https=)
IL (1) IL217887A0 (https=)
MX (1) MX2012001560A (https=)
NZ (1) NZ598518A (https=)
RU (1) RU2012108108A (https=)
SG (1) SG178226A1 (https=)
WO (1) WO2011017330A1 (https=)
ZA (1) ZA201200760B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
JP6125436B2 (ja) 2011-02-09 2017-05-10 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC 凍結乾燥製剤
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
CN111402950B (zh) * 2013-11-29 2024-03-19 豪夫迈·罗氏有限公司 抗体选择装置和方法
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
AU2015325055B2 (en) 2014-10-01 2021-02-25 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013202A1 (es) * 1997-07-10 2000-12-13 Biotech Australia Pty Ltd Vacunas no acuosas
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CN1671741A (zh) * 2002-06-21 2005-09-21 拜奥根Idec公司 浓缩抗体的缓冲剂制剂及其使用方法
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
US8236292B2 (en) * 2004-06-04 2012-08-07 Camurus Ab Liquid depot formulations
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
EA200601714A1 (ru) * 2004-06-14 2007-06-29 Ю Эс Ви ЛИМИТЕД Способ получения пептидов
US20080200383A1 (en) * 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
BRPI0620316A2 (pt) * 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos

Similar Documents

Publication Publication Date Title
JP2013501058A5 (https=)
JP2024119907A (ja) 黄色ブドウ球菌(staphylococcus aureus)感染症を治療および予防するための組成物および方法
AU2015370522B2 (en) Pharmaceutical products and stable liquid compositions of IL-17 antibodies
JP5918246B2 (ja) 抗インターロイキン−4受容体(il−4r)抗体を含有する安定化製剤
RU2012108108A (ru) Концентрированные полипептидные лекарственные формы с пониженной вязкостью
JP2008528638A5 (https=)
JP2016515124A5 (https=)
JP2017160208A5 (https=)
CN104258390A (zh) 针对人血管生成素-2的高亲和力人抗体
EP2021026A1 (en) Use of il-i antibodies for treating ophthalmic disorders
KR20160115939A (ko) 중등-용량 스타틴 치료법에 의해 적당하게 조절되지 않는 고콜레스테롤혈증이 있는 환자의 치료 방법
JP2013515071A5 (https=)
JP2017528480A5 (https=)
RU2017120361A (ru) Антитела к pdgf-b и способы их применения
CN111787981A (zh) 改变身体组成的方法
JP2019521156A5 (https=)
TW201909913A (zh) 一種sost抗體醫藥組成物及其用途
JP6663910B2 (ja) 抗TNF−α抗体療法を受けた乾癬患者を治療するための方法
JP7502286B2 (ja) 抗pcsk9抗体を含む安定製剤
JP2021523881A5 (https=)
AU2009322587B2 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
US12358977B2 (en) Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the IL-20R
JP2024542777A (ja) 多発血管炎、好酸球増多症候群、好酸球増多症候群、鼻ポリープを伴う慢性副鼻腔炎(crswnp)又は鼻ポリープを伴わない慢性副鼻腔炎(crssnp)の処置における使用のためのインターロイキン5結合タンパク質投与レジメン
TWI904235B (zh) 治療性抗體調配物
JP2021147383A (ja) アトピー性皮膚炎及び関連障害を処置するための方法